Alkermes to Acquire Avadel Pharmaceuticals for ~$2.1B, Marking its Entry in Sleep Medicine Market

Shots:Alkermes has entered into a definitive agreement to acquire Avadel, incl. its asset Lumryz, accelerating its entry into the sleep medicine marketAs per the deal, Alkermes will acquire Avadel for $18.5/share, along with one non-tradeable CVR of $1.5/share tied to Lumryz’s US FDA approval for idiopathic hypersomnia in adults by 2028 end, representing…

ByRidhi Rastogi2 days ago

INSIGHTS+

Insights+: Key Takeaways of J.P. Morgan Healthcare Conference 2023 Based on Therapeutic Areas

Shots:The 41st Annual J.P. Morgan Healthcare Conference took place on 09 – 12 January 2023 in San Francisco, CA, USA. It is the largest and most informative healthcare investment symposium in the industry, bringing together a cohort of industry leaders, emerging fast-growing companies, innovative technology creators, and members of the investment community The major announcement…

BySenior EditorJanuary 19, 2023

INSIGHTS+

Insights+: Key Deals of J.P. Morgan Healthcare Conference 2020

The 2020 JP Morgan Healthcare Conference was loaded with insights from key pharma companies. An analysis of events and catalysts that were announced or updated at the conference these days are included. Our PharmaShots team summarized the key deals which were presented during the updates from companies from Jan 13 to Jan 16, 2020.Date…

BySenior EditorFebruary 7, 2020

INSIGHTS+

Insights+: The US FDA New Drug Approvals in September and October 2019

The US FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 35 new products so far in 2019. In 2018 FDA approved 59 novel products including 42 New Chemical Entities and 17 Biologics while breaking its last year's record of approvals. However, there is a significant…

BySenior EditorNovember 15, 2019

Alkermes to Acquire Avadel Pharmaceuticals for ~$2.1B, Marking its Entry in Sleep Medicine Market

Insights+: Key Takeaways of J.P. Morgan Healthcare Conference 2023 Based on Therapeutic Areas

Insights+: Key Deals of J.P. Morgan Healthcare Conference 2020

Insights+: The US FDA New Drug Approvals in September and October 2019

Contact US

OUR INFORMATION

FOLLOW US